China Immunotech (beijing) Biotechnology Co., Ltd.

This is an early-stage safety study testing a single infusion of YTS109 cells in 18 adults with severe autoimmune diseases that have not responded to standard treatments. The main goal is to check for side effects and see how the body handles the cells. Researchers will also look…

This is an early safety study testing a single infusion of a new cell therapy called YTS109. It aims to see if the treatment is safe and shows any signs of helping adults with severe autoimmune diseases that have not responded to standard treatments. The study will enroll about 1…

This is an early-stage study to check the safety of a new cell therapy called YTS109 for adults with severe autoimmune diseases that have not responded to standard treatments. About 18 participants with conditions like lupus, scleroderma, or vasculitis will receive a single infus…

This is an early-stage study to check the safety of a new cell therapy called YTS109 in adults with severe autoimmune diseases that have not improved with standard treatments. About 18 participants with conditions like lupus, Sjogren's syndrome, or vasculitis will receive a singl…